Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis

BACKGROUND: Pirfenidone was recently approved for treatment of idiopathic pulmonary fibrosis. However, the therapeutic dose of pirfenidone is very high, causing side effects that limit its doses and therapeutic effectiveness. Understanding the molecular mechanisms of action of pirfenidone could impr...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Respir Res
Main Authors: Xie, Yan, Jiang, Haihong, Zhang, Qian, Mehrotra, Suneet, Abel, Peter W., Toews, Myron L., Wolff, Dennis W., Rennard, Stephen, Panettieri, Reynold A., Casale, Thomas B., Tu, Yaping
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4994235/
https://ncbi.nlm.nih.gov/pubmed/27549302
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-016-0418-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados